Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Part 1 of the study will first evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant and will confirm the recommended doses (RDs) of ZW25 and palbociclib in this combination. Part 2 of the study will evaluate the anti-tumor activity of the combination of ZW25 with palbociclib plus fulvestrant at the RD level in patients with HER2-positive, HR-positive advanced breast cancer.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N2
- Tom Baker Cancer Centre
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Canada, M4N3M5
- Sunnybrook Research Institute
-
-
Quebec
-
Montreal, Quebec, Canada, H3T1E2
- Jewish General Hospital
-
-
-
-
-
Barcelona, Spagna, 08035
- Hospital Universitario Vall d'Hebrón
-
Madrid, Spagna, 28034
- Hospital Ruber Internacional
-
Málaga, Spagna, 29010
- Hospital Universitario Virgen de la Victoria
-
Seville, Spagna, 41013
- Hospital Universitario Virgen del Rocío
-
Valencia, Spagna, 46010
- Hospital Clínico Universitario de Valencia
-
-
Alicante
-
Elche, Alicante, Spagna, 03203
- Hospital General Universitario de Elche
-
-
-
-
California
-
Santa Monica, California, Stati Uniti, 90404
- UCLA Hematology/Oncology Parkside
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Sarah Cannon Research Institute
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Seattle Cancer Care Alliance
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Pathologically-confirmed diagnosis of breast cancer with evidence of locally advanced (unresectable) and/or metastatic disease. All patients in both Parts 1 and 2 must have HER2-positive and HR-positive disease.
- Received prior treatment with trastuzumab, pertuzumab, AND ado-trastuzumab emtansine (T-DM1); disease progression during or after the most recent prior therapy. Patients in any part of the study who did not receive pertuzumab or T-DM1 because of lack of access (e.g., due to insurance coverage or because they were treated prior to regulatory agency approval of the agent in a relevant indication) or due to medical ineligibility for treatment with T-DM1 (e.g., history of severe infusion reactions to trastuzumab, >/= Grade 2 peripheral neuropathy, or platelet count < 100 x 10^9/L) may be eligible for the study. Prior treatment with endocrine therapy in the neoadjuvant, adjuvant, and/or metastatic setting is permitted.
- Sites of disease assessible per RECIST version 1.1 (both measurable and non-measurable disease allowed)
- An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate organ function
- Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) >/= institutional standard of normal
Exclusion Criteria:
- Prior treatment with trastuzumab, pertuzumab, lapatinib, T-DM1, or other anti-HER2-targeted therapy </= 3 weeks before the first dose of ZW25
- Prior treatment with chemotherapy, other anti-cancer therapy not otherwise specified, or hormonal cancer therapy </= 3 weeks before the first dose of ZW25
- Prior treatment with palbociclib or any other CDK4/6 inhibitor, including experimental agents
- History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)
- QTc Fridericia (QTcF) > 470 ms
- Grade 2 or greater pneumonitis and/or interstitial lung disease, including pulmonary fibrosis, or other clinically significant infiltrative pulmonary disease not related to lung metastases
- Active hepatitis B or hepatitis C infection
- Acute or chronic uncontrolled renal disease, pancreatitis, or severe liver disease (Child-Pugh Class C)
- Known infection with Human Immunodeficiency Virus (HIV)-1 or HIV-2 (Exception: patients with well controlled-HIV [e.g., cluster of differentiation 4 (CD4)-positive T-cell count > 350 mm3 and undetectable viral load] are eligible.)
- Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Brain metastases: Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off steroids and anticonvulsants and are neurologically stable for at least 1 month at the time of screening).
- History of or ongoing leptomeningeal disease
- Grade 3 or greater peripheral neuropathy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: ZW25 (zanidatamab) + palbociclib + fulvestrant
Participants who received intravenous dose of 20 mg/kg ZW25 (zanidatamab) every 2 weeks (Q2W) in combination with an oral administration of 125 mg palbociclib once daily from Days 1 to 21, and an intramuscular injection of 500 mg fulvestrant Q2W for 3 doses (Cycle 1 Days 1 and 15 and Cycle 2 Day 1), and every 4 weeks (Q4W) thereafter. |
Administered orally Administered intravenously Administered as an intramuscular injection |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities
Lasso di tempo: Cycle 1 Day 1 to Day 28 (each cycle is 28 days)
|
Dose-limiting toxicities, defined using NCI CTCAE version 5.0, are events that 1) occur following administration of ZW25, palbociclib, and fulvestrant; and 2) meet the criteria as specified in the protocol. |
Cycle 1 Day 1 to Day 28 (each cycle is 28 days)
|
|
Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events
Lasso di tempo: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.
|
A treatment-emergent adverse event occurs after the start of study treatment and is defined as any unfavorable or unintended symptom, sign, or disease (including abnormal lab) temporally associated with the use of treatment that may or may not be considered related to treatment. TEAEs were coded using MedDRA v24.0. |
From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.
|
|
Progression-free Survival 6
Lasso di tempo: 6 months from first dose of all study drugs to the date of documented disease progression or death
|
The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days). |
6 months from first dose of all study drugs to the date of documented disease progression or death
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants Reporting Any Treatment-emergent Adverse Event, Serious Adverse Event, and Adverse Event of Special Interest
Lasso di tempo: From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days
|
A treatment-emergent adverse events (TEAEs) was defined as an adverse event (AE) with onset on or after 1st dose of study treatment through 30 days after final dose of study treatment inclusive. An AE is classified as a serious adverse event (SAE) if fatal, life threatening, requires hospitalization, is disabling/incapacitating, causes congenital anomaly or birth defect, and medically significant. Adverse events of special interest (AESI) include absolute decrease in LVEF greater than or equal to 10 percentage points from baseline and LVEF value less than 50% post-baseline or LVEF value greater than or equal to 20% to less than or equal to 39% post baseline, symptomatic heart failure, infusion-related reactions, and all greater than or equal to Grade 2 events of pneumonitis and/or interstitial lung disease, including pulmonary fibrosis. |
From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days
|
|
Maximum Serum Concentration Steady State of ZW25
Lasso di tempo: End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA). |
End of ZW25 infusion on Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
|
Trough Concentration Steady State of ZW25
Lasso di tempo: Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
Pharmacokinetics (PK) were evaluated using noncompartmental analysis (NCA). |
Predose at Cycle 4 Day 1 (steady state) (each cycle is 28 days)
|
|
Number of Participants With Anti-drug Antibodies (ADAs) Post-baseline
Lasso di tempo: Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.
|
Participants were considered to be ADA positive if they were initially ADA negative at baseline and tested positive for ADAs following study drug exposure ("treatment-induced ADA response"), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater than the titer of the baseline sample ("treatment-enhanced ADA response"). Participants were considered to be ADA negative if they were ADA negative at baseline and all post-baseline samples were negative, or if they were ADA positive at baseline but did not have any post-baseline samples with a titer that was at least 4-fold greater than the titer of the baseline sample ("treatment-unaffected ADA"). |
Predose at Cycle 1 Days 1 and 15; Cycle 2 Days 1 and 15; Cycle 4 Day 1 and subsequent ADA assessment visits; end of treatment; 30 days post last dose (safety FU); and every 8 weeks (efficacy FU) (each cycle, 28 days), up to approximately 5 years 20 days.
|
|
Objective Response Rate
Lasso di tempo: From first dose of treatment up to end of study, approximately 5 years 20 days
|
Confirmed objective response rate is defined as the number of patients with confirmed complete response (CR) and confirmed partial response (PR). CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions as assessed by the Investigator per RECIST v1.1. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Duration of Response
Lasso di tempo: From first dose of treatment up to end of study, approximately 5 years 20 days
|
DOR is defined as the time from the first confirmed objective response (CR or PR) to documented PD per RECIST 1.1 or death within 30 days of last dose of study drug (ZW25, palbociclib, and/or fulvestrant) from any cause. Only participants who achieved a confirmed objective response were included in the analysis. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Disease Control Rate
Lasso di tempo: From first dose of treatment up to end of study, approximately 5 years 20 days
|
Disease control is defined as a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD per RECIST 1.1. The proportion of participants who achieve a disease control response was calculated. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Progression-free Survival
Lasso di tempo: From first dose of treatment up to end of study, approximately 5 years 20 days
|
Progression-free survival (PFS) time is defined as the time from first dose of ZW25, palbociclib, and/or fulvestrant to the date of first documented disease progression (per RECIST 1.1) or death from any cause, whichever occurs first. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Overall Survival
Lasso di tempo: From first dose of treatment up to end of study, approximately 5 years 20 days
|
OS is defined as time from first dose of ZW25, palbociclib, and/or fulvestrant until death from any cause. |
From first dose of treatment up to end of study, approximately 5 years 20 days
|
|
Incidence of Abnormal Hepatic Lab Values
Lasso di tempo: From first dose of treatment up to end of study, approximately 5 years 20 days
|
From first dose of treatment up to end of study, approximately 5 years 20 days
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie della pelle
- Malattie del seno
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Composti policiclici
- Steroidi
- Composti anelli fusi
- Estradiolo
- Estrene
- Estrane
- Congeneri di estradiolo
- Ormoni steroidi gonadali
- Ormoni gonadali
- Fulvestrant
- Palbociclib
- Zanidatamab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ZWI-ZW25-202
- 2019-002956-18 (Numero EudraCT)
- 2019 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .